LINK . SPRINGER . COM {}

Detected CMS Systems:

Wordpress (10 occurrences)

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Link.springer.com Make Money
Wordpress Themes And Plugins
Keywords
Topics
Questions
Schema
External Links
Analytics And Tracking
Libraries
CDN Services

We are analyzing https://link.springer.com/article/10.1007/s11060-024-04682-7.

Title:
Global post‑marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011–2022 | Journal of Neuro-Oncology
Description:
Background Tumor Treating Fields (TTFields) are alternating electric fields that disrupt cancer cell processes. TTFields therapy is approved for recurrent glioblastoma (rGBM), and newly-diagnosed (nd) GBM (with concomitant temozolomide for ndGBM; US), and for grade IV glioma (EU). We present an updated global, post-marketing surveillance safety analysis of patients with CNS malignancies treated with TTFields therapy. Methods Safety data were collected from routine post-marketing activities for patients in North America, Europe, Israel, and Japan (October 2011–October 2022). Adverse events (AEs) were stratified by age, sex, and diagnosis. Results Overall, 25,898 patients were included (diagnoses: ndGBM [68%], rGBM [26%], anaplastic astrocytoma/oligodendroglioma [4%], other CNS malignancies [2%]). Median (range) age was 59 (3–103) years; 66% patients were male. Most (69%) patients were 18–65 years; 0.4% were < 18 years; 30% were > 65 years. All-cause and TTFields-related AEs occurred in 18,798 (73%) and 14,599 (56%) patients, respectively. Most common treatment-related AEs were beneath-array skin reactions (43%), electric sensation (tingling; 14%), and heat sensation (warmth; 12%). Treatment-related skin reactions were comparable in pediatric (39%), adult (42%), and elderly (45%) groups, and in males (41%) and females (46%); and similar across diagnostic subgroups (ndGBM, 46%; rGBM, 34%; anaplastic astrocytoma/oligodendroglioma, 42%; other, 40%). No TTFields-related systemic AEs were reported. Conclusions This long-term, real-world analysis of > 25,000 patients demonstrated good tolerability of TTFields in patients with CNS malignancies. Most therapy-related AEs were manageable localized, non-serious skin events. The TTFields therapy safety profile remained consistent across subgroups (age, sex, and diagnosis), indicative of its broad applicability.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Insurance
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Link.springer.com is based on WORDPRESS.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could be secretly minting cash, but we can't detect the process.

Wordpress Themes and Plugins {🎨}

What WordPress theme does this site use?

It is strange but we were not able to detect any theme on the page.

What WordPress plugins does this website use?

It is strange but we were not able to detect any plugins on the page.

Keywords {🔍}

patients, ttfields, therapy, pubmed, article, fields, google, scholar, tumor, treating, aes, safety, skin, cancer, data, central, analysis, glioblastoma, age, oncol, cas, novocure, cns, reported, clinical, ndgbm, years, treatment, study, patient, table, pediatric, system, sensation, systemic, profile, electric, cell, gbm, common, elderly, device, global, surveillance, events, tumors, including, postmarketing, related, arrays,

Topics {✒️}

uh=18f20e383178129b5d6cd118075549592bae498860854e0293f947072990624c&administrationurl=https%3a%2f%2foptunelua-admin /pdfs/optune-lua-mpm-ifu de/wp-content/uploads/2020/11/optune_user_manual_ver2 small-cell lung cancer included low-grade gliomas tumour treating fields tumour-treating fields unsolicited post-marketing surveillance post-marketing surveillance data routine post-marketing activities high-grade gliomas article download pdf post-marketing surveillance analysis moisture-related stresses related central nervous system tumor-treating fields elicit tumor-treating fields—reply org/professionals/physician_gls/pdf/cns /sites/patient/files/2023-11/optune_ifu prevent life-threatening illness cell membrane permeability device-related aes specific including high-risk pediatric prospective post-approval study generation novottf-100a system ttfields-related aes occurred ttfields therapy-related falls real-world data expand generation novottf-200a system generation novottf-200a system malignant brain tumors high-grade glioma device-related aes occurring life-threatening electric shocks ttfields-related systemic aes registry/real-world data novottf-100a versus physician real-world safety data life-threatening illness/injury oberheim bush na karanam nk oberheim-bush na large cohort size common treatment-related aes treatment-related skin reactions cancer cell viability long-term data demonstrate beneath-array skin reactions high-risk patient population ttfields-related ‘qol decreased

Questions {❓}

Org/articles/who-classification-of-cns-tumours-1?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Global post‑marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011–2022
         description:Tumor Treating Fields (TTFields) are alternating electric fields that disrupt cancer cell processes. TTFields therapy is approved for recurrent glioblastoma (rGBM), and newly-diagnosed (nd) GBM (with concomitant temozolomide for ndGBM; US), and for grade IV glioma (EU). We present an updated global, post-marketing surveillance safety analysis of patients with CNS malignancies treated with TTFields therapy. Safety data were collected from routine post-marketing activities for patients in North America, Europe, Israel, and Japan (October 2011–October 2022). Adverse events (AEs) were stratified by age, sex, and diagnosis. Overall, 25,898 patients were included (diagnoses: ndGBM [68%], rGBM [26%], anaplastic astrocytoma/oligodendroglioma [4%], other CNS malignancies [2%]). Median (range) age was 59 (3–103) years; 66% patients were male. Most (69%) patients were 18–65 years; 0.4% were < 18 years; 30% were > 65 years. All-cause and TTFields-related AEs occurred in 18,798 (73%) and 14,599 (56%) patients, respectively. Most common treatment-related AEs were beneath-array skin reactions (43%), electric sensation (tingling; 14%), and heat sensation (warmth; 12%). Treatment-related skin reactions were comparable in pediatric (39%), adult (42%), and elderly (45%) groups, and in males (41%) and females (46%); and similar across diagnostic subgroups (ndGBM, 46%; rGBM, 34%; anaplastic astrocytoma/oligodendroglioma, 42%; other, 40%). No TTFields-related systemic AEs were reported. This long-term, real-world analysis of > 25,000 patients demonstrated good tolerability of TTFields in patients with CNS malignancies. Most therapy-related AEs were manageable localized, non-serious skin events. The TTFields therapy safety profile remained consistent across subgroups (age, sex, and diagnosis), indicative of its broad applicability.
         datePublished:2024-06-29T00:00:00Z
         dateModified:2024-06-29T00:00:00Z
         pageStart:25
         pageEnd:38
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1007/s11060-024-04682-7
         keywords:
            Tumor Treating Fields
            TTFields
            Glioblastoma
            Brain tumor
            High grade gliomas
            Safety
            Oncology
            Neurology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-024-04682-7/MediaObjects/11060_2024_4682_Fig1_HTML.png
         isPartOf:
            name:Journal of Neuro-Oncology
            issn:
               1573-7373
               0167-594X
            volumeNumber:169
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Maciej M. Mrugala
               affiliation:
                     name:Mayo Clinic College of Medicine and Science, Mayo Clinic
                     address:
                        name:Mayo Clinic College of Medicine and Science, Mayo Clinic, Phoenix/Scottsdale, Arizona, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Wenyin Shi
               affiliation:
                     name:Thomas Jefferson University
                     address:
                        name:Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Fabio Iwomoto
               affiliation:
                     name:New York-Presbyterian/Columbia University Medical Center
                     address:
                        name:Division of Neuro-Oncology, New York-Presbyterian/Columbia University Medical Center, New York, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rimas V. Lukas
               affiliation:
                     name:Northwestern University
                     address:
                        name:Department of Neurology, Northwestern University, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Joshua D. Palmer
               affiliation:
                     name:The James Cancer Hospital, Ohio State University Wexner Medical Center
                     address:
                        name:The Department of Radiation Oncology, The James Cancer Hospital, Ohio State University Wexner Medical Center, Columbus, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:John H. Suh
               affiliation:
                     name:Taussig Cancer Institute, Cleveland Clinic
                     address:
                        name:Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Martin Glas
               affiliation:
                     name:University Hospital Essen, University Duisburg-Essen, West German Cancer Center (WTZ) and German Cancer Consortium
                     address:
                        name:Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, West German Cancer Center (WTZ) and German Cancer Consortium, Essen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Global post‑marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011–2022
      description:Tumor Treating Fields (TTFields) are alternating electric fields that disrupt cancer cell processes. TTFields therapy is approved for recurrent glioblastoma (rGBM), and newly-diagnosed (nd) GBM (with concomitant temozolomide for ndGBM; US), and for grade IV glioma (EU). We present an updated global, post-marketing surveillance safety analysis of patients with CNS malignancies treated with TTFields therapy. Safety data were collected from routine post-marketing activities for patients in North America, Europe, Israel, and Japan (October 2011–October 2022). Adverse events (AEs) were stratified by age, sex, and diagnosis. Overall, 25,898 patients were included (diagnoses: ndGBM [68%], rGBM [26%], anaplastic astrocytoma/oligodendroglioma [4%], other CNS malignancies [2%]). Median (range) age was 59 (3–103) years; 66% patients were male. Most (69%) patients were 18–65 years; 0.4% were < 18 years; 30% were > 65 years. All-cause and TTFields-related AEs occurred in 18,798 (73%) and 14,599 (56%) patients, respectively. Most common treatment-related AEs were beneath-array skin reactions (43%), electric sensation (tingling; 14%), and heat sensation (warmth; 12%). Treatment-related skin reactions were comparable in pediatric (39%), adult (42%), and elderly (45%) groups, and in males (41%) and females (46%); and similar across diagnostic subgroups (ndGBM, 46%; rGBM, 34%; anaplastic astrocytoma/oligodendroglioma, 42%; other, 40%). No TTFields-related systemic AEs were reported. This long-term, real-world analysis of > 25,000 patients demonstrated good tolerability of TTFields in patients with CNS malignancies. Most therapy-related AEs were manageable localized, non-serious skin events. The TTFields therapy safety profile remained consistent across subgroups (age, sex, and diagnosis), indicative of its broad applicability.
      datePublished:2024-06-29T00:00:00Z
      dateModified:2024-06-29T00:00:00Z
      pageStart:25
      pageEnd:38
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1007/s11060-024-04682-7
      keywords:
         Tumor Treating Fields
         TTFields
         Glioblastoma
         Brain tumor
         High grade gliomas
         Safety
         Oncology
         Neurology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-024-04682-7/MediaObjects/11060_2024_4682_Fig1_HTML.png
      isPartOf:
         name:Journal of Neuro-Oncology
         issn:
            1573-7373
            0167-594X
         volumeNumber:169
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Maciej M. Mrugala
            affiliation:
                  name:Mayo Clinic College of Medicine and Science, Mayo Clinic
                  address:
                     name:Mayo Clinic College of Medicine and Science, Mayo Clinic, Phoenix/Scottsdale, Arizona, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Wenyin Shi
            affiliation:
                  name:Thomas Jefferson University
                  address:
                     name:Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Fabio Iwomoto
            affiliation:
                  name:New York-Presbyterian/Columbia University Medical Center
                  address:
                     name:Division of Neuro-Oncology, New York-Presbyterian/Columbia University Medical Center, New York, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rimas V. Lukas
            affiliation:
                  name:Northwestern University
                  address:
                     name:Department of Neurology, Northwestern University, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Joshua D. Palmer
            affiliation:
                  name:The James Cancer Hospital, Ohio State University Wexner Medical Center
                  address:
                     name:The Department of Radiation Oncology, The James Cancer Hospital, Ohio State University Wexner Medical Center, Columbus, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:John H. Suh
            affiliation:
                  name:Taussig Cancer Institute, Cleveland Clinic
                  address:
                     name:Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Martin Glas
            affiliation:
                  name:University Hospital Essen, University Duisburg-Essen, West German Cancer Center (WTZ) and German Cancer Consortium
                  address:
                     name:Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, West German Cancer Center (WTZ) and German Cancer Consortium, Essen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal of Neuro-Oncology
      issn:
         1573-7373
         0167-594X
      volumeNumber:169
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Mayo Clinic College of Medicine and Science, Mayo Clinic
      address:
         name:Mayo Clinic College of Medicine and Science, Mayo Clinic, Phoenix/Scottsdale, Arizona, USA
         type:PostalAddress
      name:Thomas Jefferson University
      address:
         name:Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, USA
         type:PostalAddress
      name:New York-Presbyterian/Columbia University Medical Center
      address:
         name:Division of Neuro-Oncology, New York-Presbyterian/Columbia University Medical Center, New York, USA
         type:PostalAddress
      name:Northwestern University
      address:
         name:Department of Neurology, Northwestern University, Chicago, USA
         type:PostalAddress
      name:The James Cancer Hospital, Ohio State University Wexner Medical Center
      address:
         name:The Department of Radiation Oncology, The James Cancer Hospital, Ohio State University Wexner Medical Center, Columbus, USA
         type:PostalAddress
      name:Taussig Cancer Institute, Cleveland Clinic
      address:
         name:Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA
         type:PostalAddress
      name:University Hospital Essen, University Duisburg-Essen, West German Cancer Center (WTZ) and German Cancer Consortium
      address:
         name:Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, West German Cancer Center (WTZ) and German Cancer Consortium, Essen, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Maciej M. Mrugala
      affiliation:
            name:Mayo Clinic College of Medicine and Science, Mayo Clinic
            address:
               name:Mayo Clinic College of Medicine and Science, Mayo Clinic, Phoenix/Scottsdale, Arizona, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Wenyin Shi
      affiliation:
            name:Thomas Jefferson University
            address:
               name:Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Fabio Iwomoto
      affiliation:
            name:New York-Presbyterian/Columbia University Medical Center
            address:
               name:Division of Neuro-Oncology, New York-Presbyterian/Columbia University Medical Center, New York, USA
               type:PostalAddress
            type:Organization
      name:Rimas V. Lukas
      affiliation:
            name:Northwestern University
            address:
               name:Department of Neurology, Northwestern University, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Joshua D. Palmer
      affiliation:
            name:The James Cancer Hospital, Ohio State University Wexner Medical Center
            address:
               name:The Department of Radiation Oncology, The James Cancer Hospital, Ohio State University Wexner Medical Center, Columbus, USA
               type:PostalAddress
            type:Organization
      name:John H. Suh
      affiliation:
            name:Taussig Cancer Institute, Cleveland Clinic
            address:
               name:Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA
               type:PostalAddress
            type:Organization
      name:Martin Glas
      affiliation:
            name:University Hospital Essen, University Duisburg-Essen, West German Cancer Center (WTZ) and German Cancer Consortium
            address:
               name:Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, West German Cancer Center (WTZ) and German Cancer Consortium, Essen, Germany
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Mayo Clinic College of Medicine and Science, Mayo Clinic, Phoenix/Scottsdale, Arizona, USA
      name:Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, USA
      name:Division of Neuro-Oncology, New York-Presbyterian/Columbia University Medical Center, New York, USA
      name:Department of Neurology, Northwestern University, Chicago, USA
      name:The Department of Radiation Oncology, The James Cancer Hospital, Ohio State University Wexner Medical Center, Columbus, USA
      name:Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA
      name:Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, West German Cancer Center (WTZ) and German Cancer Consortium, Essen, Germany

External Links {🔗}(256)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.76s.